The legacy of Viagra and its influence on the pharmaceutical sector presents a challenging question regarding its continued attractiveness as an investment. Initially a remarkable success, generating vast revenues, generic competition has considerably eroded financial returns. While established pharmaceutical firms hold patents on related therapies

The performance of companies tied to flagship drugs like Viagra presents a challenging investment landscape . While the initial surge of copyright, fueled by Viagra's unprecedented popularity, generated substantial profits , the loss of exclusivity in key territories has introduced substantial risk . Investors are now assessing the effect of generi